Sign in
Taking people in United StatesNo phase

Registry tracking treatment and health of people with myeloma and amyloidosis

Collects information, blood samples and bone marrow tissue from adults with plasma cell diseases.

Key facts

Who runs it
Ohio State University Comprehensive Cancer Center
Where
Columbus, United StatesSee the site
Trial code
Registry title
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Status
Recruiting
People taking part
5,000 people, planned
Started
17 Mar 2011
Expected to end
Mar 2050
Type of study
Observational
Treatments tested
  • tissue banking
Record updated
23 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who have been diagnosed with a plasma cell disease, such as multiple myeloma or amyloidosis. It collects information and samples for research.

Age
18 years and older
Sex
Women and men can join.
Disease stage
A diagnosis of a plasma cell dyscrasia (a disease of the plasma cells).

Main reasons for not taking part

  • Prisoners cannot join.

The registry criteria, word for word

Show all 4 criteriaShow less

Other criteria

  • Inclusion:
  • Diagnosis of a plasma cell dyscrasia
  • Exclusion:
  • Prisoners are excluded from participation as they have no standard access to the Ohio State myeloma clinic and would impede the research objective of this protocol

Where in United States

  • Ohio State University Medical CenterColumbus, United StatesContact: Don BensonTaking people

About the trial

What the trial wants to find out

The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals:

Read full original descriptionShow less

* Surveillance: The investigators want to track what treatments patients get or don't get, how effective they are, how they feel, what complications they suffer, how long they stay in remission, and how long they live. * Contact: Because myeloma and amyloidosis are rare, less than 700 patients are diagnosed in the state of Ohio each year, patients often feel they don't have accurate information. The investigators want to provide them access to our clinical team (both phone and email consultations, even office visits for patients that can come to Columbus) as well as information regarding informational events pertaining to your disease and local support groups. * Research: Because nearly all myeloma and amyloid patients relapse and treatment is eventually unsuccessful, our focus is to develop more effective treatments that not only prolong life, but cure the disease. Periodically the investigators will inform them about clinical trials studying new drugs or treatment paradigms.

Treatments tested

  • tissue banking

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis
Plain-language title
Registry tracking treatment and health of people with myeloma and amyloidosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
23 March 2026